US Patent

US11590137 — Ruxolitinib formulation for reduction of itch in atopic dermatitis

Method of Use · Assigned to Incyte Corp · Expires 2040-09-04 · 14y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of reducing itch in patients with atopic dermatitis by administering a topical ruxolitinib cream.

USPTO Abstract

This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3505`	—	ruxolitinib-phosphate

Patent Metadata

Patent number: US11590137
Jurisdiction: US
Classification: Method of Use
Expires: 2040-09-04
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.